Recurrent Thrombotic Events after Discontinuation of Vitamin K Antagonist Treatment for Splanchnic Vein Thrombosis: A Multicenter Retrospective Cohort Study
Table 3
Characteristics of patients with vascular events during follow-up.
Variable
Patients with vascular events ( = 7)
Patients without vascular events ( = 83)
Age (years), median (IQR)
47 (31–62)
50 (40–62)
Males, (%)
4 (57.1%)
43 (51.8%)
Personal history VTE, (%)
1 (14.3%)
6 (7.2%)
Family history VTE, (%)
1 (14.3%)
7 (8.4%)
Unprovoked SVT, (%)
2 (28.6%)
31 (37.4%)
Liver cirrhosis, (%)
3 (42.9%)
11 (13.3%)
Solid cancer, (%)
0 (0%)
6 (7.2%)
Myeloproliferative neoplasm, (%)
1 (14.3%)
6 (7.2%)
Recent abdominal surgery, (%)
0 (0%)
10 (12.1%)
Hormonal therapy, (%
1 (33.3%)
10 (25.0%)
Inflammatory bowel disease, (%)
0 (0%)
5 (6.0%)
JAK2 V617F mutation, (%
1 (20.0%)
2 (5.4%)
Factor V Leiden or prothrombin G20210A mutation, (%
1 (20.0%)
8 (16.0%)
Previous VKA treatment duration (months), median (IQR)
9.9 (3.2–12.9)
12.7 (7.2–24.0)
Time within therapeutic range (%), median (IQR)
68 (67–80)
62 (56–75)
Antiplatelet therapy during follow-up, (%)
2 (28.6%)
12 (14.5%)
Percentage calculated on the female population. Percentage calculated on the number of tested patients. IQR = interquartile range, SVT = splanchnic vein thrombosis, VKA = vitamin K antagonist, and VTE = venous thromboembolism.
